The first generic! Osekon Pharmaceuticals TPO-R agonisant is listed.

As a non-peptide oral TPO receptor agonis, apopaethanolamine tablets can bind to TPO receptors (trans membrane regions) on the cell membrane, activate signal transduction pathways, stimulate the differentiation and proliferation of human bone marrow progenitor cells to macronuclear cells, and promote the maturation of macronuclear cells, thereby increasing platelet production. At the same time
, aiquupa ethanol amine tablets and endogenous TPO function site is different, will not compete with the endogenous TPO receptor, so the two will not form competitive inhibition, and may be synergy, jointly improve platelet count.
Novartis' Rifland was approved in China in December 2017 and officially listed in July 2018 for platelet reduction in patients with chronic primary immunooplatelet altruism (ITP) patients who have been treated with glucocorticosteroids, immunoglobulin treatments, or chronic primary immunonostysis (ITP) after spleen removal.
primary immune platelet reduction, formerly known as ilate platelet reduction cyanosis, its pathogenesis is due to the human body's "blood-clotting guardian" platelets based on some obtained autoimmune reasons can not reach the normal number, resulting in more bleeding, unable to clot.
it is understood that, as the preferred solution of ITP second-line treatment, Rifran can not only quickly increase the number of platelets, but also the use of convenient oral methods, improve the compliance of medication, for patients to provide a new treatment options.
only Novartis's Rifland has been approved in China.
but public information shows that, in addition to Theaikang Pharmaceuticals, Qilu Pharmaceuticals, Zhengda Tianqing and other companies are also carrying out auquipa ethanol amine tablets human bioequivalence test.
in fact, TPO-R has become one of the hot targets for enterprise research and development, and five TPO-R drugs have been approved worldwide, namely reeds, apophepa, Romistin, Ava poop and platelet generator.
many Chinese companies are now joining the research and development boom of such drugs.
in April this year, Fosun Pharma introduced a new platelet reduction drug, Avalquo Patablet tablets, has been approved for use in patients with chronic liver disease in adults planning invasive surgery for platelet reduction.
not long ago, Hengrui Pharmaceuticals also submitted a listing application in China for a new class of new drug Haiqupopa ethanolamine tablets, which is an oral small molecule non-peptide platelet-inducing receptor (TPO-R) agonis.
hope that these TPO-R drug research in the study will be carried out smoothly and benefit patients as soon as possible.
.